70.48
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$68.72
Offen:
$69.422
24-Stunden-Volumen:
3.12M
Relative Volume:
0.71
Marktkapitalisierung:
$218.58B
Einnahmen:
$54.98B
Nettoeinkommen (Verlust:
$7.77B
KGV:
28.31
EPS:
2.49
Netto-Cashflow:
$9.14B
1W Leistung:
+0.23%
1M Leistung:
+0.76%
6M Leistung:
+3.34%
1J Leistung:
-10.97%
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
70.48 | 218.02B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
2025-02-13 | Hochstufung | UBS | Neutral → Buy |
2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
2024-11-20 | Hochstufung | UBS | Sell → Neutral |
2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
2024-05-30 | Eingeleitet | Goldman | Buy |
2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
2024-01-16 | Fortgesetzt | UBS | Sell |
2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
2023-12-18 | Eingeleitet | HSBC Securities | Buy |
2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-07-12 | Hochstufung | UBS | Neutral → Buy |
2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-08-29 | Hochstufung | Argus | Hold → Buy |
2022-06-14 | Herabstufung | UBS | Buy → Neutral |
2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
2021-04-12 | Herabstufung | Argus | Buy → Hold |
2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
2021-02-25 | Hochstufung | UBS | Neutral → Buy |
2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-11-30 | Hochstufung | UBS | Sell → Neutral |
2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
2020-09-29 | Eingeleitet | Berenberg | Buy |
2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
2019-10-25 | Hochstufung | Liberum | Hold → Buy |
2019-04-02 | Herabstufung | UBS | Neutral → Sell |
2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
2018-12-11 | Fortgesetzt | Jefferies | Hold |
2018-10-09 | Eingeleitet | Guggenheim | Buy |
2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
2018-02-05 | Bestätigt | Bernstein | Outperform |
2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca vows to spend US$50bil on US manufacturing boost - thestar.com.my
AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats - insights.citeline.com
AstraZeneca commits $50 billion to US pharmaceutical manufacturing and R&D - BioProcess International
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US - Benzinga
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy - Benzinga
AstraZeneca to invest $50 bn in the US as tariff threat looms - Yahoo.co
AstraZeneca to invest $50B in US to boost drug manufacturing and R&D - Proactive financial news
AstraZeneca’s Phase 2 Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s New Trial: A Step Forward in Liver Fibrosis Treatment? - TipRanks
Fear of tariffs? AstraZeneca calls $50 billion US investment a ‘deliberate choice’ - Euractiv
AstraZeneca’s Tozorakimab Study: A Potential Game-Changer in COPD Treatment - TipRanks
AstraZeneca’s Phase 4 Study on Tezepelumab: A Boost for Severe Asthma Treatment - TipRanks
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures - TradingView
AstraZeneca picks Virginia for multibillion-dollar manufacturing site - Richmond Times-Dispatch
Lockheed Martin, AstraZeneca, DR Horton: Trending Tickers - Yahoo Finance
Astrazeneca, Phillip Morris & D.R. Horton earnings: Trending Tickers - Yahoo.co
AstraZeneca announces $50 billion US investment in manufacturing and R&D By Investing.com - Investing.com Australia
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D July 22, 2025 - James Sharp & Co.
AZN to invest $50bn in US, targets $80bn revenue by 2030 | AZN SEC FilingForm 6-K - Stock Titan
Global pharma companies do record deals with Chinese biotechs - Financial Times
Trending tickers: AstraZeneca, Verizon, Opendoor, Trump Media and Lindt & Spruengli - Yahoo.co
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms - Reuters
Astra Pledges $50 Billion on US Manufacturing, Development - Bloomberg.com
AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - MSN
AstraZeneca announces $50bn US investment in manufacturing and R&D - Proactive financial news
AstraZeneca unveils plans for £37bn investment in US amid tariff threats - Yahoo.co
AstraZeneca to invest $50bn in the US amid fears it could quit Britain - The Telegraph
AstraZeneca pledges $50bn in US investment as Trump pharma tariffs loom - Financial Times
AstraZeneca Vows to Spend $50 Billion on US Manufacturing, Development - MSN
AstraZeneca to invest $50bn in US after Trump tariff threat - The Times
Astrazeneca plots huge $50bn US investment after ditching UK expansion plans - Yahoo.co
AstraZeneca says to invest $50 bn in the US - Yahoo.co
AstraZeneca To Invest $50 Bln In U.S. By 2030 To Boost Medicine Production And Research - Nasdaq
AstraZeneca vows to spend $50 billion on US manufacturing, development - CNBC TV18
AstraZeneca grows US presence with $50B in spending plans - BioPharma Dive
AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com
AstraZeneca to invest $50B in US economy by 2030 - AOL.com
AstraZeneca to invest $50B in US by 2030 - breakingthenews.net
AstraZeneca to spend $50-billion to expand manufacturing, research capabilities in U.S. - The Globe and Mail
What analysts say about AstraZeneca PLC Depositary Receipt stockPowerful profit generation - Autocar Professional
AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer - Yahoo Finance
AstraZeneca’s Observational SLE Study in Kazakhstan: Key Insights for Investors - TipRanks
AstraZeneca Plans Massive $50B US Investment: New Virginia Mega-Factory to Create Thousands of Jobs - Stock Titan
AstraZeneca’s Promising Pediatric SLE Study: Anifrolumab’s Potential Impact - TipRanks
AstraZeneca’s New Phase II Study: A Potential Breakthrough in Liver Cancer Treatment - TipRanks
AstraZeneca’s COPD Study: Potential Game-Changer for Cardiopulmonary Outcomes - TipRanks
AstraZeneca’s AIRSUPRA Study: A Potential Game-Changer in Asthma Treatment - TipRanks
What drives AstraZeneca PLC Depositary Receipt stock priceRapid wealth multiplication - Autocar Professional
AstraZeneca reports positive results from Tagrisso combo trial - Seeking Alpha
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters - Stocktwits
AstraZeneca’s lung cancer drug shows improved survival with chemotherapy combo - Investing.com UK
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):